Nasdaq · Biotech stocks database
ANAB (AnaptysBio Inc.) stock: $46.37, $1.37B market cap, $153.0M cash, $1.48B EV, $1.83B fully diluted market cap. Lead program: Rosnilimab (Rheumatoid Arthritis), Phase 2. Data from Fully Diluted's biotech stocks database.
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $153.0M |
|---|---|
| Debt | $0.0M |
| Royalty-sale liability | $263.7M |
| Net cash | $153.0M |
| Enterprise value | $1,483.5M |
| Basic shares | 29.7M shares |
| Fully diluted shares | 39.6M shares |
| Fully diluted market cap | $1,834.1M |
| Cash per share | $5.15 |
| Quarterly burn | $25.9M |
| Cash runway | 11.1 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.
Royalty-sale liability as of 2026-03-31 (10-Q); included in enterprise value.
Cap table as of 2026-03-31.
Loading ANAB daily closes…
Quimilza (imsidolimab) · Dec 12, 2026 · guided in 28d